Activated CDC42 kinase 1, also known as ACK1, is an enzyme that in humans is encoded by the TNK2gene.
[1][2][3][4][5]
TNK2 gene encodes a non-receptor tyrosine kinase, ACK1, that binds to multiple receptor tyrosine kinases e.g. EGFR, MERTK, AXL, HER2 and insulin receptor (IR). ACK1 also interacts with Cdc42Hs in its GTP-bound form and inhibits both the intrinsic and GTPase-activating protein (GAP)-stimulated GTPase activity of Cdc42Hs. This binding is mediated by a unique sequence of 47 amino acids C-terminal to an SH3 domain. The protein may be involved in a regulatory mechanism that sustains the GTP-bound active form of Cdc42Hs and which is directly linked to a tyrosine phosphorylation signal transduction pathway. Several alternatively spliced transcript variants have been identified from this gene, but the full-length nature of only two transcript variants has been determined.[5]
ACK1 or TNK2 has been shown to interact with AKT,[3] Androgen receptor or AR,[6] a tumor suppressor WWOX,[7]FYN[8] and Grb2.[9][10] ACK1 interaction with its substrates resulted in their phosphorylation at specific tyrosine residues. ACK1 has been shown to directly phosphorylate AKT at tyrosine 176, AR at Tyrosine 267 and 363, and WWOX at tyrosine 287 residues, respectively. ACK1-AR signaling has also been reported to regulate ATM levels,[11]
Clinical relevance
ACK1 is a survival kinase and shown to be associated with tumor cell survival, proliferation, hormone-resistance and radiation resistance.[1] The activation of ACK1 has been observed in prostate, breast, pancreatic, lung and ovarian cancer cells.[1][3][6][12] ACK1 transgenic mice, expressing activated ACK1 specifically in prostate gland has been reported; these mice develop prostatic intraepithelial neoplasia (PINs).[3]
ACK1 inhibitors
Ack1 has emerged as a new cancer target and multiple small molecule inhibitors have been reported.[13][14][15] All of these inhibitors are currently in the pre-clinical stage.
↑Manser E, Leung T, Salihuddin H, Tan L, Lim L (June 1993). "A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42". Nature. 363 (6427): 364–7. doi:10.1038/363364a0. PMID8497321.
↑Yokoyama N, Miller WT (November 2003). "Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck". J Biol Chem. 278 (48): 47713–23. doi:10.1074/jbc.M306716200. PMID14506255.
↑Mahajan NP, Whang YE, Mohler JL, Earp HS (November 2005). "Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox". Cancer Res. 65 (22): 10514–23. doi:10.1158/0008-5472.can-05-1127. PMID16288044.
↑Linseman DA, Heidenreich KA, Fisher SK (February 2001). "Stimulation of M3 muscarinic receptors induces phosphorylation of the Cdc42 effector activated Cdc42Hs-associated kinase-1 via a Fyn tyrosine kinase signaling pathway". J. Biol. Chem. 276 (8): 5622–8. doi:10.1074/jbc.M006812200. PMID11087735.
↑Satoh T, Kato J, Nishida K, Kaziro Y (May 1996). "Tyrosine phosphorylation of ACK in response to temperature shift-down, hyperosmotic shock, and epidermal growth factor stimulation". FEBS Lett. 386 (2–3): 230–4. doi:10.1016/0014-5793(96)00449-8. PMID8647288.
↑Kato-Stankiewicz J, Ueda S, Kataoka T, Kaziro Y, Satoh T (June 2001). "Epidermal growth factor stimulation of the ACK1/Dbl pathway in a Cdc42 and Grb2-dependent manner". Biochem. Biophys. Res. Commun. 284 (2): 470–7. doi:10.1006/bbrc.2001.5004. PMID11394904.
Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Satoh T, Kato J, Nishida K, Kaziro Y (1996). "Tyrosine phosphorylation of ACK in response to temperature shift-down, hyperosmotic shock, and epidermal growth factor stimulation". FEBS Lett. 386 (2–3): 230–4. doi:10.1016/0014-5793(96)00449-8. PMID8647288.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.
Mott HR, Owen D, Nietlispach D, et al. (1999). "Structure of the small G protein Cdc42 bound to the GTPase-binding domain of ACK". Nature. 399 (6734): 384–8. doi:10.1038/20732. PMID10360579.
Eisenmann KM, McCarthy JB, Simpson MA, et al. (2000). "Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas". Nat. Cell Biol. 1 (8): 507–13. doi:10.1038/70302. PMID10587647.
Kato J, Kaziro Y, Satoh T (2000). "Activation of the guanine nucleotide exchange factor Dbl following ACK1-dependent tyrosine phosphorylation". Biochem. Biophys. Res. Commun. 268 (1): 141–7. doi:10.1006/bbrc.2000.2106. PMID10652228.
Owen D, Mott HR, Laue ED, Lowe PN (2000). "Residues in Cdc42 that specify binding to individual CRIB effector proteins". Biochemistry. 39 (6): 1243–50. doi:10.1021/bi991567z. PMID10684602.
Kiyono M, Kato J, Kataoka T, et al. (2000). "Stimulation of Ras guanine nucleotide exchange activity of Ras-GRF1/CDC25(Mm) upon tyrosine phosphorylation by the Cdc42-regulated kinase ACK1". J. Biol. Chem. 275 (38): 29788–93. doi:10.1074/jbc.M001378200. PMID10882715.
Linseman DA, Heidenreich KA, Fisher SK (2001). "Stimulation of M3 muscarinic receptors induces phosphorylation of the Cdc42 effector activated Cdc42Hs-associated kinase-1 via a Fyn tyrosine kinase signaling pathway". J. Biol. Chem. 276 (8): 5622–8. doi:10.1074/jbc.M006812200. PMID11087735.
Teo M, Tan L, Lim L, Manser E (2001). "The tyrosine kinase ACK1 associates with clathrin-coated vesicles through a binding motif shared by arrestin and other adaptors". J. Biol. Chem. 276 (21): 18392–8. doi:10.1074/jbc.M008795200. PMID11278436.
Kato-Stankiewicz J, Ueda S, Kataoka T, et al. (2001). "Epidermal growth factor stimulation of the ACK1/Dbl pathway in a Cdc42 and Grb2-dependent manner". Biochem. Biophys. Res. Commun. 284 (2): 470–7. doi:10.1006/bbrc.2001.5004. PMID11394904.
Oda T, Muramatsu MA, Isogai T, et al. (2001). "HSH2: a novel SH2 domain-containing adapter protein involved in tyrosine kinase signaling in hematopoietic cells". Biochem. Biophys. Res. Commun. 288 (5): 1078–86. doi:10.1006/bbrc.2001.5890. PMID11700021.
Ahmed I, Calle Y, Sayed MA, et al. (2004). "Cdc42-dependent nuclear translocation of non-receptor tyrosine kinase, ACK". Biochem. Biophys. Res. Commun. 314 (2): 571–9. doi:10.1016/j.bbrc.2003.12.137. PMID14733946.
Gu Y, Lin Q, Childress C, Yang W (2004). "Identification of the region in Cdc42 that confers the binding specificity to activated Cdc42-associated kinase". J. Biol. Chem. 279 (29): 30507–13. doi:10.1074/jbc.M313518200. PMID15123659.
Brandenberger R, Wei H, Zhang S, et al. (2005). "Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation". Nat. Biotechnol. 22 (6): 707–16. doi:10.1038/nbt971. PMID15146197.
Lougheed JC, Chen RH, Mak P, Stout TJ (2004). "Crystal structures of the phosphorylated and unphosphorylated kinase domains of the Cdc42-associated tyrosine kinase ACK1". J. Biol. Chem. 279 (42): 44039–45. doi:10.1074/jbc.M406703200. PMID15308621.